Profile data is unavailable for this security.
About the company
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
- Revenue in USD (TTM)0.00
- Net income in USD-17.09m
- Incorporated2017
- Employees31.00
- LocationMink Therapeutics Inc149 Fifth Avenue, Suite 500NEW YORK 10010United StatesUSA
- Phone+1 (212) 994-8250
- Fax+1 (302) 655-5049
- Websitehttps://www.minktherapeutics.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 27.67m | 8.00 | -- | 1.41 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Vyne Therapeutics Inc | 486.00k | -27.86m | 28.02m | 10.00 | -- | 0.3689 | -- | 57.66 | -2.41 | -2.57 | 0.0162 | 5.15 | 0.0087 | -- | -- | 48,600.00 | -49.92 | -108.41 | -59.60 | -138.57 | -- | -- | -5,732.31 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| ImmuCell Corp | 23.22m | -4.05m | 28.43m | 74.00 | -- | 1.21 | -- | 1.22 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Impact Biomedical Inc | 0.00 | -4.25m | 28.97m | 1.00 | -- | 1.24 | -- | -- | -0.3694 | -0.3694 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -9.59 | -- | -15.04 | -- | -- | -- | -- | -- | -- | -5.12 | 0.3377 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -2.01m | 29.28m | -- | -- | -- | -- | -- | -0.1562 | -0.1562 | 0.00 | -0.2067 | 0.00 | -- | -- | -- | -199.80 | -- | -- | -- | -- | -- | -- | -- | -- | -15.58 | -- | -- | -- | -- | -72.57 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 29.58m | 23.00 | -- | 1.33 | -- | 24.07 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Mink Therapeutics Inc | 0.00 | -17.09m | 30.33m | 31.00 | -- | -- | -- | -- | -0.4891 | -0.4891 | 0.00 | -0.4202 | 0.00 | -- | -- | 0.00 | -152.35 | -- | -4,151.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 30.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 31.09m | 20.00 | -- | 2.42 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Lumos Pharma Inc | 1.49m | -35.75m | 31.85m | 33.00 | -- | 3.10 | -- | 21.43 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.66m | 32.23m | 41.00 | -- | 0.3276 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Aligos Therapeutics Inc | 7.97m | -75.74m | 32.54m | 68.00 | -- | 0.9515 | -- | 4.08 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Quince Therapeutics Inc | 0.00 | -53.12m | 32.89m | 32.00 | -- | 0.7003 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 234.18k | 0.59% |
| Longbow Finance SA (Switzerland)as of 30 Jun 2024 | 166.67k | 0.42% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 127.84k | 0.32% |
| Geode Capital Management LLCas of 30 Jun 2024 | 96.35k | 0.24% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 83.12k | 0.21% |
| Hightower Advisors LLCas of 30 Jun 2024 | 50.69k | 0.13% |
| CapFinancial Partners LLCas of 30 Jun 2024 | 35.73k | 0.09% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 25.52k | 0.07% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 17.56k | 0.04% |
| Millennium Management LLCas of 30 Jun 2024 | 13.12k | 0.03% |
